全社ベースの売上総利益は前年同期比11.6%減の25,101百万円、売上総利益率は同1.5ポイント低下して79.3%となった。販管費は同19.5%減少し、販管費率は同8.8ポイント低下して74.5%となった。販管費のうち広告宣伝費は同25.6%減少し、売上高に対する比率は同11.3ポイント低下して53.7%となった。なお四半期別に見ると、第1四半期は売上高が16,142百万円で営業利益が601百万円、第2四半期は売上高が15,510百万円で営業利益が933百万円だった。広告宣伝投資の適正化などにより、2023年7月期第2四半期より営業利益の計上定着している。■Performance Trends
1. Consolidated financial results summary for the 2nd quarter of the fiscal year ending July 2024
The consolidated financial results for the second quarter of the fiscal year ending 2024/7 of Pharma Foods ＜2929＞ were sales of 31,652 million yen, down 9.9% from the same period last year, operating income of 1,535 million yen (loss of 883 million yen in the same period last year), ordinary profit of 1,542 million yen (loss of 912 million yen), and quarterly net profit attributable to parent company shareholders of 768 million yen (loss of 914 million yen). As for sales, although the BtoB business expanded steadily, sales declined due to the effects of declining operating rates of production contractors in the BtoC business and manufacturing delays due to shipment restrictions of raw material manufacturers. Meanwhile, since advertising costs declined drastically due to the effects of putting advertising of new products in the BtoC business backwards, each profit turned into a surplus and landed.
Total profit on a company-wide basis was 25,101 million yen, down 11.6% from the same period last year, and gross profit margin fell 1.5 points to 79.3%. SG&A expenses decreased 19.5% from the same period, and the SG&A fee ratio fell 8.8 points to 74.5%. Of the SG&A expenses, advertising expenses decreased by 25.6% from the same period, and the ratio to sales fell 11.3 points to 53.7%. Looking at each quarter, sales for the first quarter were 16,142 million yen and operating profit was 601 million yen, while sales for the second quarter were 15,510 million yen and operating profit was 933 million yen. Operating profit has been recorded since the 2nd quarter of the fiscal year ending 2023/7 due to optimization of advertising investments, etc.
(Author: FISCO Visiting Analyst Masashi Mizuta Exhibition)
